The rare pediatric disease priority review voucher, explained
A tradable right to faster FDA review has become one of the more valuable prizes in paediatric drug development. Whether it creates new medicines is still debated.
In brief
How the FDA rare pediatric disease priority review voucher works, why vouchers sell for around $100m, and whether the scheme creates new medicines.
- Created by Congress in 2012, the voucher is awarded on approval of a qualifying rare paediatric disease drug.
- It entitles the holder to priority review of a different, later application, and it can be sold.
- Sale prices have commonly run to around $100 million.
The rare pediatric disease priority review voucher programme was created by the Food and Drug Administration Safety and Innovation Act of 2012. Its premise is simple. If a company wins approval for a drug that treats a serious or life-threatening rare disease primarily affecting children, the FDA gives it a voucher.
What the voucher does
The voucher can be redeemed for priority review of a future application, for any drug, in any disease. Priority review sets a six-month goal for an FDA decision, against ten months under standard review. For a product with large expected sales, reaching the market several months sooner can be worth a great deal.
Crucially, vouchers are transferable. A small biotech that wins one can sell it to a large company with a blockbuster in the queue. Prices have varied, but sales of around $100 million have been common, and a few have gone for considerably more.
Does it work?
That is the contested part. For a small company developing a drug for a rare paediatric condition, the prospect of a voucher worth nine figures can make an otherwise marginal programme financeable. Supporters point to the stream of rare paediatric approvals since 2012 as evidence that the incentive matters.
Critics argue that many of those drugs would have been developed anyway, that the voucher rewards approval rather than innovation, and that priority review for an unrelated product shifts FDA resources rather than creating them. Government reviews have found it difficult to show that the programme changed which drugs were developed.
A recurring fight in Congress
Unlike permanent parts of the FDA’s toolkit, the paediatric voucher programme has been subject to sunset dates, and its renewal has repeatedly been tied up in wider legislative negotiations. Each lapse creates uncertainty for companies whose financing assumes a voucher at the end of development.
For investors and business development teams, the lesson is to treat the voucher as a policy-dependent asset: valuable when available, but not something to bank on years before approval.
